Call for Papers for Special Issue ‘Integrative Omics Study for Clinical Liver Disease’ May 24, 2022 As a major cause of morbidity and mortality, clinical liver disease (CLD) has become a severely increasing global burden due to its occupancy of health resources for patient treatment. Many pharmacological approaches (such as targeted therapy) or surgical techniques (such as live transplantation and associating liver partition and portal vein ligation for staged hepatectomy [ALPPS]) may help to improve the prognosis of patients with CLD. However, the underlying pathological mechanism of disease and the rationality of these therapies have yet to be revealed. A comprehensive understanding of the mechanisms of the occurrence and development of CLD and the relevant therapeutic approaches will support efforts for better prevention and therapy from the perspective of precision medicine.

Call for Papers for Special Issue ‘Artificial Intelligence in Liver Disease- Step towards Precision Medicine’ March 18, 2022 Artificial intelligence (AI) is the new era of data science and is rapidly gaining utility in the health sector. Given the demonstrated performance of AI in different domains and the rapid progress of methodology improvement, deep learning paradigms have introduced exciting and new opportunities for biomedical informatics.

Call for Papers for Special Issue ‘Acute liver failure (ALF)’ March 30, 2021 Acute liver failure (ALF) is a rare and severe consequence of abrupt hepatocyte injury, and can evolve over days or weeks to a lethal outcome. Although liver transplantation used in nearly 30% patients with ALF has resulted in lower mortality, it is still a life-threatening severe disease. Research on the pathogenesis and treatment of ALF is still active.

Call for Papers for Special Issue ‘Metabolic dysfunction-associated fatty liver disease (MAFLD)’ March 24, 2021 Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as Nonalcoholic Fatty Liver Disease (NAFLD), is recently proposed nomenclature with a new set of diagnostic criteria. With an estimated 2 billion people being affected around the world, MAFLD signifies a growing global health burden, and such health challenge is expected to grow in the coming decade and especially among demographics with higher rate of obesity. Currently, MAFLD is recognized to increase the risk for higher severity in patients with the COVID-19.

Call for Papers for Special Issue ‘Coronavirus Disease (COVID-19) and the Liver’ June 3, 2020 The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), is now a global pandemic, but a huge knowledge gap remains about the effects of this novel virus on the human body. Because angiotensin-converting enzyme 2 (ACE2), the reported receptor for SARS-CoV-2, is highly expressed in almost the entire gastrointestinal tract, a significant portion of patients develop elevated liver enzyme levels and gastrointestinal symptoms, but the underlying pathophysiology is obscure.